Immunophotonics is thrilled to be showcased as the Member Highlight for March by The Missouri Biotechnology Association #MOBIO, both on their homepage & in the March newsletter. This recognition underscores Immunophotonics commitment to advancing life science research.

Tomas Hode, PhD, who serves as the Co-Founder, CIO, and President at Immunophotonics, Inc., is eager to attend the AngioDynamics International Life Symposium “The Human Touch, behind Innovation” scheduled for March 21-23 in Rome. #LifeSymposium #immunophotonics #innovation

Tomas Hode, PhD, who serves as the Co-Founder, CIO, & President at Immunophotonics is excited to attend the European Conference on Interventional Oncology (#ECIO2024) in Palma de Mallorca, Spain, from April 28-May 1. #interventionaloncology #ablation #immunooncology #innovati

Immunophotonics, Inc. is delighted to introduce Jacqueline Hess as the newest addition to our advisory board. Ms. Hess has over 25 years of Big 4 experience supporting U.S. biotech companies that are expanding globally, with a particular focus on the U.S.-Swiss business corridor.

Immunophotonics is pleased to announce the appointment of Dr. Maziar Assadi Gehr in the role of Medical Director. Dr. Gehr will spearhead the development of our pivotal trial, drawing upon his extensive expertise in various facets of the drug development process.

Immunophotonics Lu Alleruzzo (CEO) & Tomas Hode, PhD (CIO & President) will be in Chicago at the ASCO annual meeting, May 31-June 3. They are thrilled to engage with clinical experts worldwide, explore cutting-edge research, and discover innovative treatments. #ASCO24

Immunophotonics is excited to share that Dr. Robert CG Martin II, M.D, PhD, will be presenting his IRE data at the Central Surgical Association 81st Annual Meeting on June 6 at 9:10 am in the SCIENTIFIC SESSION I, Medallion Ballroom AB. #interventionaloncology #ablation #cancer

Lu Alleruzzo, CEO, Tomas Hode, PhD, CIO & President, along with the Immunophotonics Team, extend their congratulations to Professor Wei Chen, co-inventor of IP-001, for being honored as one of the Class of 2024 Senior Members by the National Academy of Inventors (NAI) #innovation

Immunophotonics is excited to announce the Cancer Center Amsterdam at Amsterdam UMC received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics' ablation devices.

Immunophotonics featured in Pharma Tech Outlook magazine. Immunophotonics innovative approach could transform standard treatments into powerful immunotherapies with IP-001 turning every procedure into an opportunity to mobilize the body’s natural immune system against cancer.

Prof. Wei Chen & his team recently organized a session titled “Immunophotonics” for the Gordon Research Conf. Optics & Photonics in Medicine & Biology in Lewiston, ME. Prof. Chen delivered an oral presentation on "Localized Immunophotonics for the Treatment of Metastatic Cancers"

We are thrilled to announce that Dr. Robert Martin has successfully enrolled & treated the 1st patient in our groundbreaking clinical trial: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma.

Immunophotonics is thrilled to have won the Startup World Cup St. Louis Regional finals. A big thank you to Emily Hemingway and her team at TechSTL for their hard work in organizing this remarkable event. You did an exceptional job! Silicon Valley here we come!

Immunophotonics Lu Alleruzzo (CEO), Tomas Hode, PhD (CIO & President), & David Anderson (CSO) are excited to be attending CIRSE Congress taking place in Lisbon, Portugal, Sept. 14 -18th & ESMO Congress in Barcelona, Spain on Sept. 16th. Be sure to visit our Booth 60 at CIRSE.

Immunophotonics Lu Alleruzzo, CEO &Tomas Hode, PhD, CIO, & President are pleased to announce a collaboration with CIRSE, support preparations for a groundbreaking Phase 2/3 clinical trial: INJECTABL-3. The trial will be managed by CIRSE’s CRO - Next Research.

Immunophotonics wants to congratulate Prof. Wei Chen & his lab at University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K. Lam, Tomas Hode, David Anderson, Johnny Wong, Abby Delawder, Joe Raker of Immunophotonics, for their publication in Advanced Science News.

Siu Kit “Samuel” Lam, PhD, Senior Vice President of Science & Research at Immunophotonics, Inc. attended the SITC Immuno-Oncology Drug Development Summit held in Boston from September 30 – October 1, 2024. #SITC2024 #interventionaloncology #ablation #immunooncology #cancer

Congratulations to Prof. Wei Chen & his lab Univ. of Oklahoma for their publication titled “Localized ablative immunotherapy enhances antitumor immunity by modulating the transcriptome of tumor-infiltrating Gamma delta T cells” in Elsevier Cancer Letters an international journal.

Interventional Oncology (IO) Week, organized by SIO for the 4th consecutive year, aims to raise awareness about this subspecialty of radiology that focuses on treating cancer through targeted, minimally invasive procedures performed with image guidance. #IOAwarenessweek #IKnowIO

Immunophotonics Lu Alleruzzo & Tomas Hode, PhD, will attend the AngioDynamics International Life Symposium November 7-9 in Monte Carlo. They will engage with experts globally, focusing on the latest breakthrough technologies for surgical interventions. #AngioLifeSymposium